GlassScriptPhysician profile
James J Crosswell
NPI 1407900673
$6,043.22
in general payments reported to CMS, 2019-2025
42 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $906 · 2021: $886 · 2022: $773 · 2023: $728 · 2024: $686 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,487.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $627.09 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $590.91 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $525.81 | 2020-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $504.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $461.79 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $358.18 | 2019-2025 | Trintellix |
| Pfizer INC. | $339.33 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $334.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $280.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.44 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $234.28 | 2020-2025 | Capvaxive, Gardasil 9, Verquvo |
| Novartis Pharmaceuticals Corporation | $232.92 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $202.94 | 2019-2021 | |
| Medtronic, INC. | $102.93 | 2025 | Kyphon Express II Kyphopak Tray |
| Arbor Pharmaceuticals, INC. | $88.32 | 2020-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Crosswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.